Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMBIVENT RESPIMAT vs ALA-CORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion. Albuterol stimulates beta-2 receptors, relaxing bronchial smooth muscle and increasing c AMP.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),Reversible airway disease (off-label: asthma exacerbation)
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA),Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Two inhalations (ipratropium 18 mcg and albuterol 103 mcg per inhalation) via oral inhalation four times daily. Maximum: 12 inhalations per 24 hours.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Ipratropium: terminal half-life approximately 1.6 hours. Salbutamol: terminal half-life 3.8-6 hours (mean 4.6 hours). Clinically, inhalation allows direct airway delivery; systemic half-life not primarily responsible for bronchodilator effect.
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Ipratropium: partially metabolized by ester hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfotransferase (SULT1A3) to albuterol 4'-O-sulfate.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Ipratropium: primarily fecal (70-90%) via biliary excretion, renal excretion accounts for 10-20%. Salbutamol: 60-70% renal as unchanged drug and metabolites, 30-40% fecal via biliary excretion.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Ipratropium: 0-9% (minimal). Salbutamol: 10-15% primarily to albumin.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
Ipratropium: 4.6 L/kg (large Vd indicates extensive tissue distribution). Salbutamol: 4-6 L/kg (high Vd reflects distribution into tissues).
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
Inhalation: 7-14% of delivered dose reaches systemic circulation (ipratropium 7%, salbutamol 13-14%). Oral bioavailability: ipratropium <5%, salbutamol 30-40%.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
No specific dose adjustment recommended for renal impairment. Use caution in patients with severe renal impairment (Cr Cl <30 m L/min) due to potential for systemic accumulation.
No adjustment required for topical use; systemic absorption minimal.
No specific dose adjustment recommended for hepatic impairment. Use caution in severe hepatic impairment (Child-Pugh class C) as safety data are limited.
No adjustment required for topical use; hepatic metabolism negligible.
Not established for children under 18 years. Safety and efficacy have not been determined in pediatric patients.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
No specific dose adjustment recommended. Use with caution due to increased sensitivity to anticholinergic effects (e.g., urinary retention, constipation) and beta-agonist effects (e.g., tremor, tachycardia). Monitor renal function as elderly are more prone to decreased renal function.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
None.
None
Paradoxical bronchospasm,Immediate hypersensitivity reactions (anaphylaxis, urticaria),Cardiovascular effects (increased heart rate, hypertension, QT prolongation),Use with caution in patients with glaucoma, urinary retention, or prostatic hypertrophy,Exacerbation of diabetes and ketoacidosis with albuterol,Hypokalemia with high doses of albuterol,Not for acute deterioration or rescue therapy
Systemic absorption may cause reversible HPA axis suppression,Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use,Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis,May mask signs of infection,Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression,Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician
Hypersensitivity to ipratropium, albuterol, or any component (including atropine),History of hypersensitivity to soya lecithin or peanuts (due to propellant)
Hypersensitivity to any component of the formulation,Untreated bacterial, viral, fungal, or parasitic skin infections,Viral skin infections (e.g., herpes simplex, varicella) at treatment site,Perioral dermatitis,Rosacea
No specific food interactions reported. Avoid excessive caffeine or stimulants as they may increase risk of hypokalemia and cardiac effects.
No known food interactions with topical ALA-CORT.
Ipratropium bromide and albuterol sulfate. Ipratropium: No teratogenic effects in animal studies; minimal systemic absorption suggests low fetal risk. Albuterol: Inhaled beta-agonists are not associated with major malformations; risk of preterm labor and maternal hyperglycemia. First trimester: No known teratogenicity. Second/third trimesters: May cause fetal tachycardia, hypoglycemia, and hypocalcemia if used near delivery. Overall, use only if clearly needed.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Ipratropium: Minimal excretion into breast milk due to low bioavailability; M/P ratio not established. Albuterol: Excreted into breast milk in small amounts (M/P ratio ~0.6). Doses <4 puffs/day are considered compatible with breastfeeding. Monitor infant for irritability, tachycardia, and feeding difficulties.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
No specific dose adjustments are recommended due to pregnancy. Use lowest effective dose to maintain asthma control. Inhaled route minimizes systemic exposure. Monitor for increased need due to worsening asthma during pregnancy; adjust based on clinical response.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
Combivent Respimat is a fixed-dose combination of ipratropium bromide and albuterol sulfate for maintenance treatment of COPD. It should not be used for acute exacerbations; short-acting beta-agonists are preferred. The Respimat device delivers a slow-moving aerosol; proper inhalation technique is critical. Monitor for paradoxical bronchospasm, atrial fibrillation, and hypokalemia, especially in patients with cardiac disease. May increase intraocular pressure in patients with narrow-angle glaucoma; avoid spraying into eyes.
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Use exactly as prescribed; do not use more puffs than directed.,Do not use for sudden shortness of breath; have a rescue inhaler available.,Prime the Respimat inhaler by releasing 3 sprays into the air before first use or after not using for more than 3 days.,Do not spray into eyes; if contact occurs, rinse with water and seek medical attention if symptoms persist.,Continue using regularly even if feeling well; do not stop without consulting your doctor.,Seek emergency care if breathing worsens or you develop hives, swelling, or severe dizziness.
Apply a thin layer to affected area no more than 3-4 times daily.,Do not cover with bandages or plastic unless directed by doctor.,Avoid contact with eyes, mouth, or broken skin.,Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.,Do not use for diaper dermatitis or under diapers/occlusive dressings.,Keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMBIVENT RESPIMAT vs ALA-CORT, answered by our medical review team.
COMBIVENT RESPIMAT is a Bronchodilator Combination (Anticholinergic + Beta-2 Agonist) that works by Combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion. Albuterol stimulates beta-2 receptors, relaxing bronchial smooth muscle and increasing c AMP.. ALA-CORT is a Topical Corticosteroid that works by Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMBIVENT RESPIMAT and ALA-CORT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMBIVENT RESPIMAT is: Two inhalations (ipratropium 18 mcg and albuterol 103 mcg per inhalation) via oral inhalation four times daily. Maximum: 12 inhalations per 24 hours.. The standard adult dose of ALA-CORT is: Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMBIVENT RESPIMAT and ALA-CORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMBIVENT RESPIMAT is classified as Category C. Ipratropium bromide and albuterol sulfate. Ipratropium: No teratogenic effects in animal studies; minimal systemic absorption suggests low fetal risk. Albuterol: Inhaled beta-agoni. ALA-CORT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.